Anti-Aging Patent Application Filed; Exclusive Commercial Rights to Premier Biomedical, Inc.


JACKSON CENTER, Pa., Feb. 12, 2018 (GLOBE NEWSWIRE) — Premier Biomedical, Inc. (OTC:BIEI) announced today the filing of a patent application, “Method For Slowing The Aging Process”, by Mitchel S. Felder, MD, the Chairman of the Board and Scientific Advisory Board Chairman of Premier Biomedical.  Through its exclusive patent license agreement, Premier Biomedical will have exclusive rights to practice the invention.

The patent application involves the removal of certain antigens associated with the aging process through an extracorporeal (outside the body) treatment of a patient’s blood.  By targeting these antigens with a complexing agent, causing them to bind together, they can be easily removed before returning the blood to the patient.  This process can target several known aging antigens, such as mTOR (mammalian target of rapamycin), interleukin-6, TGF-beta, oxygen free radicals, Progerin, lipofuscin, etc.

Dr. Felder stated, “This approach, which is considerably different from other currently popular approaches to slow the aging process, attempts to slow aging by utilizing the extra-corporeal removal of the specific antigens involved in the pathophysiologic process of aging in the precise picogram/ml quantities and combinations which would truly slow the aging process.”

William A. Hartman, President & CEO of Premier Biomedical, stated, “This patent application significantly advances Premier Biomedical’s intellectual property by being an extension of our existing issued patents on the treatment of disease via extra-corporeal means. What is SO EXCITING about this anti-aging patent application is:

  1. Anti-aging has been sought by mankind since the beginning of recorded time.
  2. The core of this technology is the selective removal of blood-borne antigens associated with aging and is consistent with our core technology. This is explained in the YouTube Video “A Scientific Roadmap to Cure Cancer” (
  3. We have already proven in the laboratory that we can remove selected blood-borne antigens from a mixture using our technology.
  4. Development of this technology toward commercial status could begin immediately– first in the laboratory; then in small animals; and lastly in humans.
  5. Commercial application could be accelerated since nothing will be added to human blood, rather only the offending antigens causing aging would be removed.

This could be a BLOCK BUSTER, and the development could be greatly accelerated with the availability of adequate funding.”

Dr. Felder, a prolific inventor, is Board Certified and a Diplomate of the Academy of Neurology, and holds multiple granted U.S. & foreign patents.

For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Pain Management Solutions
(814) 786-8849

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTC:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans.  Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents and patent applications, and a PCT Europe National Patent.  Founded in 2010, Premier has partnered with the University of Texas at El Paso (UTEP).  In 2016, the company began developing a line of all-natural pain relief products which they began selling in early 2017 to address the rising opioid addiction problem.  The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania.  The Company is a fully-reporting issuer whose common stock trades on the OTC marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.”  For more information please visit our website:

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995).  Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.